TREATMENT WITH LOW-DOSE CYTARABINE IN ELDERLY PATIENTS (AGE 70 YEARS OR OLDER) WITH ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION EXPERIENCE
Maël Heiblig(Université Claude Bernard Lyon 1), Xavier Thomas(Hospices Civils de Lyon), Mohamed Elhamri(Hôpital Edouard Herriot), Claudiu Plesa(Institut Mérieux (France)), Fiorenza Barraco(Hôpital Lyon Sud), Isabelle Tigaud(Inserm), Gilles Salles(Memorial Sloan Kettering Cancer Center), Eric Wattel(Université Claude Bernard Lyon 1), Mauricette Michallet(Institut d’Hématologie et d’Oncologie Pédiatrique), Franck E. Nicolini(Hôpital Edouard Herriot), Sophie Ducastelle(Hôpital Lyon Sud), Hélène Labussière(Hôpital Lyon Sud), Adriana Pleșa(Hospices Civils de Lyon)
Cited by 23
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
|Advances in Therapy|2017|603